ADPT — Adaptive Biotechnologies Corporation

Summary of Adaptive Biotechnologies Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $70.9 million, up 45% year-over-year.
• MRD Revenue: $67.1 million, reflecting a 53% increase, with clinical contributing 65% and pharma 35%.
• Immune Medicine Revenue: $3.8 million, down 26% year-over-year due to timing of sample receipts.
• Sequencing Gross Margin: 70%, an increase of 8 percentage points year-over-year.
• Adjusted EBITDA: Loss of $2.5 million, with MRD adjusted EBITDA at $12.1 million (compared to a loss of $4.1 million in the prior year).
• Net Loss: $20 million, including $2.9 million in interest expenses.

2. Strategic Updates and Business Highlights

• MRD Growth: Clinical volumes increased 41% year-over-year, with clonoSEQ tests reaching a record of nearly 32,600.
• Community Testing: Community volumes grew 67% year-over-year, now representing 35% of total testing, with strong engagement from clinicians.
• Regulatory Milestone: Recognized first primary endpoint milestone in the U.S. related to MRD in the CEPHEUS trial for multiple myeloma.
• Pricing: U.S. average selling price (ASP) increased 11% year-over-year to $1,360 per test.
• Biopharma Backlog: Increased by 24% year-over-year to approximately $254 million, with strong bookings from regulated studies.

3. Forward Guidance and Outlook

• Full Year MRD Revenue Guidance: Raised to $260 million - $270 million, up from previous guidance of $255 million - $265 million.
• Volume Growth Expectation: Anticipating at least 35% growth in clinical volumes for 2026.
• Operational Efficiency: Targeting over 70% sequencing gross margins and positive adjusted EBITDA by the end of 2026.

4. Bad News, Challenges, or Points of Concern

• Immune Medicine Revenue Decline: A significant drop of 26% year-over-year, indicating challenges in this segment.
• Regulatory Risks: Ongoing discussions regarding reimbursement structures and potential changes in Medicare policies could impact future revenue.
• Competitive Pressures: While MRD testing is gaining traction, the presence of competitors in the market raises concerns about sustaining growth and market share.

5. Notable Q&A Insights

• Community Testing Conversations: Transitioned from initial skepticism to practical implementation discussions, indicating growing acceptance of MRD testing.
• Reimbursement Stability: clonoSEQ is not currently subject to PAMA reporting requirements, which may provide a buffer against potential reimbursement changes.
• Pharma Partnerships: Increasing interest from pharmaceutical companies in utilizing MRD for clinical trials, with ongoing discussions about expanding partnerships.
• EMR Integration Progress: Early stages of optimizing integrated accounts, with a focus on maximizing pull-through rates.
• Future Growth Potential: Management expressed confidence in sustaining growth in MRD volumes and maintaining operational efficiencies despite potential market challenges.

Overall, Adaptive Biotechnologies demonstrated strong financial performance in Q1 2026, particularly in the MRD segment, while navigating challenges in the Immune Medicine area and addressing regulatory and competitive pressures. The company remains optimistic about its growth trajectory and strategic initiatives moving forward.